Soligenix (NASDAQ:SNGX) Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Soligenix (NASDAQ:SNGX) issued its earnings results on Friday. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19), Zacks reports. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.20 million. During the same quarter in the previous year, the business posted ($12.66) EPS.

Soligenix Price Performance

NASDAQ SNGX opened at $2.39 on Friday. Soligenix has a 1-year low of $1.83 and a 1-year high of $14.92. The firm has a market capitalization of $6.00 million, a P/E ratio of -0.32 and a beta of 2.03. The business’s 50-day simple moving average is $2.37 and its 200-day simple moving average is $3.12.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.